With a holistic focus on patient care and years of clinical experience and research in skin biology, we develop dermatological skincare products specifically designed to complement medical treatments and provide soothing relief for dry, itchy skin associated with certain skin conditions, including:

1. Urea associated skin conditions include:
   1. Chronic Kidney Disease associated Pruritus (CKD-aP);
   2. Vulvar Lichen Sclerosus (“VLS”); and
   3. Incontinence-Associated Dermatitis (“IAD”).
2. Inflamed and Filaggrin deficiency associated dry and itchy skin conditions:
   1. Atopic Dermatitis, Psoriasis and Sjögren; and
   2. Genetic deficiency of filaggrin involved in up to 50% of Atopic Dermatitis and Ichthyosis Vulgaris (8% of the population).
3. Post-procedure sensitive skin
   1. Inflammation following invasive aesthetic skin procedures such as micro-needling and surgery results in temporary skin barrier impairment, increased sensitivity to allergens and irritants, skin dryness and heightened immune reactivity; and
   2. Creams with high content emulsifiers may negatively impact the skin’s natural healing processes by altering lipid synthesis and protein structures crucial for recovery of the skin barrier after invasive procedures. This can slow recovery, prolong redness or swelling, and reduce the overall efficacy of aesthetic treatments.

We have established GMP manufacturing and conducted Ph2 POC clinical trials of prototype products in patients with CKD-aP (n=112) and vulvar lichen sclerosus (n=32). The compelling results are fueling our engagement in advancing optimized dermatological skincare products into commercialization under the brand name “biomee™”.

Biomee™ skin care products are uniquely formulated using our proprietary PAD Technology™ enabling a new class of cream with the following key features:

1. Ultra-pure – yet powerful: Our PAD Technology™ enables a new class of creams with unprecedented low levels of emulsifiers (soap like properties) (<0.6% compare to 3-10 % for conventional creams), minimizing wash-off of the skin’s natural microbiome and protecting lipid barrier, thereby reducing the risk of hypersensitive reactions. In addition, PAD Technology™ enables an expanded formation space allowing incorporation of higher concentrations of desired beneficial ingredients making biomee™ skincare cream more powerful.
2. Biotech-derived: Raising the bar in dermatological skin care to a new pharmaceutical standard “No compromises”. Based on our pharmaceutical development experience and follow formulation principles of FDA and EMEA. No natural ingredients, no fragrance, no “marketing ingredients”. Only 100% well characterized clinically meaningful ingredients in the right quantities, powered by PAD Technology™. Nothing else.
3. Luxurious Sensory Experience: PAD™ cream offers a luxurious, silky feel and is quickly absorbed into the skin, making it ideal for busy daily routines without leaving a greasy residue. No use of greasy wax or petrolatum.
4. PAD Technology™ is the technology and new class of cream behind FDA and EMEA approved drug:  PAD Technology™ is used in FDA and EU national authorities approved drug  Wynzora^® Cream, demonstrating its efficacy and safety in delivering delicate active ingredients to target tissue.
5. Physical Stability: The PAD Technology™ enables very robust oil droplets and formulations, enabling a broader formulation space for stability of formulations and solubility of ingredients thereby optimising delivery into the skin.
6. Eco-Friendly cold GMP Manufacturing: PAD™ creams are GMP manufactured at room temperature, significantly reducing the climate footprint compared to conventional high-temperature processes.